Beyang Therapeutics
Latest round
- Series A
Last raised
- Jul 2026
Total raised
- $30M
Investors
- 11
About Beyang Therapeutics
, trading as Beyang Therapeutics, is a pharmaceutical company that focuses on the R&D of new drugs for ocular diseases and cancer. Qiyue Hu, the company's CEO, has more than 20 years of pharmaceutical research and development, and management experience, who once worked 12 years in Pfizer and 9 years in Hengrui, respectively. As well as, he has 38 invention patents, and 30 peer-reviewed research articles., Ltd. established a proprietary computer-accelerated integrated drug discovery platform, ExCEED, which can improve the R&D efficiency and shortens the time from leads to preclinical candidates. It developed new drugs include BT01001, and BT01002. The BT01001 is a small molecule eye drop for the targeted treatment of fundus disorders. And the BT01002 is a small molecule inhibitor for the relapsed refractory subtype of high-risk leukaemia. The company's revenue is generated by providing a proprietary computer-accelerated integrated drug discovery platform, ExCEED, which utilizes novel molecular generation and optimization method MMPT and in silico DMPK simulation prediction to guide the discovery and development of preclinical candidate molecules.
Who invested in Beyang Therapeutics
11 investors across 2 rounds
See all investors in Beyang Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Beyang Therapeutics
Who invested in Beyang Therapeutics?
Beyang Therapeutics has 11 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Beyang Therapeutics raised?
Beyang Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Beyang Therapeutics last raise money?
Beyang Therapeutics's most recent round on record is a Series A, in Jul 2026.
What does Beyang Therapeutics do?
, trading as Beyang Therapeutics, is a pharmaceutical company that focuses on the R&D of new drugs for ocular diseases and cancer.
Where is Beyang Therapeutics headquartered?
Beyang Therapeutics is headquartered in Shanghai, China.
Which VCs invest in companies like Beyang Therapeutics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back pharmaceuticals companies at Beyang Therapeutics's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like Beyang Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.